Udai Banerji

This paper develops folate-olaparib conjugates that selectively enter FR-overexpressing tumor cells via endocytosis and inhibit PARylation.

This paper identifies cross resistance between cancer drugs using single-drug exposure data, showing that high cross resistance reduces the effectiveness of switching between CDK4/6 inhibitors.

This paper develops an in silico model to predict personalized therapeutic combinations for NSCLC by simulating genetic profiles and testing drug combinations to overcome resistance.

This paper demonstrates evolutionary herding in non-small cell lung cancer to control drug resistance by shifting clonal composition and inducing collateral sensitivity.